5 improvements to EHR design to protect patient data

The Electronic Health Record Association (EHRA) has released its "Electronic Health Record Design Patterns for Patient Safety" report on the relationship between usability and patient safety in regards to electronic health records (EHRs). The report outlines five areas for improvement in securing patient data when using EHRs.

The report includes input from software engineers, human factors experts and clinicians to examine current EHR usability and security. The improvements in EHR design include:

  1. Medications: Medication information should be properly displayed in accordance with the U.S. Food and Drug Administration-approved list of “Generic Drug Names with Tall Man Letters" and the Institute for Safe Medication Practices’ list of "Additional Drug Names with Tall Man Letters"; space out information on drug labels; support the use of Universal Medication Schedule displays.
  2. Alert Fatigue: Differentiate alerts by low, medium and high severity; severity level should determine intrusiveness; use a standard structure for all alerts.
  3. Lab Results: Display numeric and text results clearly; distinguish between new and previous results; use consistent formatting for abnormal results; provide graphical displays of results over time.
  4. Numeric Display: Use a comma to separate digits in sets of three; zeros should be displayed before the decimal in fractional numbers; do not use trailing zero in precision measurements; right-justify and decimal-align numbers when they're displayed in a column.
  5. Displaying Text: Reduce truncated data; use abbreviations sparingly; clearly define the difference in "no value recorded" and "actually no value"; consistently place labels adjacent to values.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.